Cardiff Oncology Stock Analysis

Cardiff Stock Analysis Notes

About 22.0% of the company shares are held by institutions such as insurance companies. The book value of Cardiff Oncology was currently reported as 1.36. The company recorded a loss per share of 0.9. Cardiff Oncology last dividend was issued on the 20th of February 2019. The entity had 1:6 split on the 20th of February 2019. Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Cardiff Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people. For more info on Cardiff Oncology please contact Mark Erlander at 858 952 7570 or go to https://www.cardiffoncology.com.

Cardiff Oncology Investment Alerts

Cardiff Oncology Upcoming and Recent Events

Cardiff Largest EPS Surprises

View All Earnings Estimates

Cardiff Oncology Environmental, Social, and Governance (ESG) Scores

Cardiff Stock Institutional Investors

Note, although Cardiff Oncology's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cardiff Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 119.45 M.

Cardiff Profitablity

Management Efficiency

Cardiff Oncology has return on total asset (ROA) of (0.3066) % which means that it has lost $0.3066 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5112) %, meaning that it created substantial loss on money invested by shareholders. Cardiff Oncology's management efficiency ratios could be used to measure how well Cardiff Oncology manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.53. The Cardiff Oncology's current Return On Capital Employed is estimated to increase to -0.61. At this time, Cardiff Oncology's Non Currrent Assets Other are most likely to increase significantly in the upcoming years. The Cardiff Oncology's current Net Tangible Assets is estimated to increase to about 128.4 M, while Total Assets are projected to decrease to roughly 45.3 M.

Technical Drivers

As of the 19th of June, Cardiff Oncology shows the Standard Deviation of 5.14, mean deviation of 3.61, and Risk Adjusted Performance of (0.10). Cardiff Oncology technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Cardiff Oncology information ratio, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Cardiff Oncology is priced correctly, providing market reflects its regular price of 2.5 per share. Please also double-check Cardiff Oncology jensen alpha, which is currently at (0.93) to validate the company can sustain itself at a future point.

Cardiff Oncology Price Movement Analysis

Cardiff Oncology Insider Trading Activities

Cardiff Oncology Predictive Daily Indicators

Cardiff Oncology Corporate Filings

Cardiff Oncology Forecast Models

Cardiff Oncology's time-series forecasting models are one of many Cardiff Oncology's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cardiff Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cardiff Oncology prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cardiff shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cardiff Oncology. By using and applying Cardiff Stock analysis, traders can create a robust methodology for identifying Cardiff entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cardiff analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cardiff analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Cardiff Oncology stock analysis indicators help investors evaluate how Cardiff Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cardiff Oncology shares will generate the highest return on investment. By understating and applying Cardiff Oncology stock analysis, traders can identify Cardiff Oncology position entry and exit signals to maximize returns.

When running Cardiff Oncology's price analysis, check to measure Cardiff Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiff Oncology is operating at the current time. Most of Cardiff Oncology's value examination focuses on studying past and present price action to predict the probability of Cardiff Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardiff Oncology's price. Additionally, you may evaluate how the addition of Cardiff Oncology to your portfolios can decrease your overall portfolio volatility.